Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Pareesh Phulkar
pareesh@coherentmarketinsights.com
www.coherentmarketinsights.com/

Bookmark and Share
Antithrombin Market Growth Opportunities, Share & Competitive Landscape Report To 2026
Improving healthcare infrastructure in emerging economies such as China and India, and increasing research and development activities are contributing towards the growth


Antithrombin Market
BriefingWire.com, 9/13/2019 - Improving healthcare infrastructure in emerging economies such as China and India, and increasing research and development activities are contributing towards the growth of antithrombin market in Asia Pacific region. For instance, in 2016, China Biologic Products, Inc.’s subsidiary, Shandong Taibang Biological Products Co. Ltd., recently obtained approval from the China Food and Drug Administration (CFDA) to begin human clinical trials using its Human Antithrombin III (ATIII) product for the treatment of hereditary and acquired ATIII deficiency which are more prone during surgical or obstetrical procedures, and treatment of thromboembolism.

Increasing regulations on animal testing have impeded a number of healthcare companies from manufacturing new drugs, thereby restraining the market growth.

Get PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/2018

The antithrombin market is characterized by the presence of few established players. There is stiff competition in the market, as these few players occupy major market share. Key players operating in the global antithrombin market include Grifols, Shire Plc., rEVO Biologics Inc., CSL Limited, Kedrion S.p.A, Lee Bisolutions, Scripps Laboratories Inc., GTC Biotherapeutics, Inc.’s, Green Cross Corp., and BDI Pharma.

Increasing incidence of coagulation disorders, open heart surgeries, and extracorporeal circulation during hemodialysis is augmenting growth of antithrombin market. Therapeutic drug pipeline or advancements in drug administering technology is also expected to fuel growth of antithrombin market. For instance, Fitusiran (ALN-AT3), developed by Alnylam Pharmaceuticals, Inc., is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT). This therapeutic that can be used for the treatment of hemophilia and rare bleeding disorders (RBDs) is in late stage (Phase 2-phase 3) clinical trial.

According to the NCBI (National Center for Biotechnology Information), inherited antithrombin deficiency is a rarely occurring deficiency and only a maximum of 0.2% of the global population has this deficiency. One of the most popular drugs for the treatment of antithrombin deficiency available in the market is ATryn, which was developed by rEVO Biologics and received the U.S. Food and Drug Administration (FDA) approval in 2009. Antithrombin shows synergistic activity with heparin that enhances the antithrombin binding with Thrombin (factor II a) and Factor Xa. Antithrombin III blood test is required to measure the amount of deficiency of antithrombin that is causing the blood to clot more easily than normal.

Antithrombin Market – Taxonomy - On the basis of application, the global antithrombin market is segmented into: Therapeutics, Research, Diagnostics,. On the basis of source, the global antithrombin market is segmented into: Human, Goat Milk, Others,. On the basis of dosage form, the global antithrombin market is segmented into: Lyophilized, Liquid,. On the basis of region, the global antithrombin market is segmented into: North America, Latin America, Europe, Asia Pacific, Middle East, Africa,.

Moreover, GTC Biotherapeutics, Inc.’s product called as ATryn Antithrombin (Recombinant), derived from human blood donors, is used for

Browse more detail information about: [FURL=https://www.coherentmarketinsights.com/ongoing-insight/antithrombin-market-2018]https://www.coherentmarketinsights.com/ongoing-insight/antithrombin-market-2018

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.